Compare QUALCOMM, Inc. (QCOM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QUALCOMM, Inc. vs TransMedics Group Inc — how do they compare? QUALCOMM, Inc. trades at $174.1 (market cap $187.95B), while TransMedics Group Inc trades at $77.5 (market cap $2.74B). The key difference: QUALCOMM, Inc. is far larger — about 68.6× TransMedics Group Inc's market cap, and QUALCOMM, Inc. pays a 2.09% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold QUALCOMM, Inc. for 87 Days and TransMedics Group Inc for 24 Days on average.
| QCOM | TMDX | |
|---|---|---|
Market Cap | $187.95B | $2.74B |
Volume | 9,535,042 | 949,331 |
Sector | Technology | Health |
52-Week High | $251.10 | $150.42 |
52-Week Low | $124.07 | $61.99 |
Typical Hold Time | 87 Days | 24 Days |
Enterprise Value | $194.92B | $3.13B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qualcomm (QCOM) trades at $177.06, down 2.21% today, with a bearish technical signal and support near $175. The company reported strong revenue of $44.28B in 2025 but net income fell to $5.54B, reflecting margin pressure. Recent news highlights a strategic AI partnership with Amazon, potentially opening a $60B opportunity, while analyst consensus remains mixed with a $204.48 price target.
QCOM's outlook is balanced by AI growth potential against near-term headwinds. The Amazon deal and diversification into automotive and data centers offer upside, but execution risks, competition, and dependence on smartphone markets pose challenges. Valuation metrics like a P/E of 20.12 appear reasonable if AI initiatives accelerate revenue.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
